AM-AF study
- Conditions
- atrial fibrillationD001281
- Registration Number
- JPRN-jRCTs071190005
- Lead Sponsor
- Kitamura Kazuo
- Brief Summary
Only 3 patients were enrolled, namely 1 for adrenomedullin group and 2 for control group, and only 1 patient who had received adrenomedullin relapsed atrial fibrillation within 3 days after catheter ablation. And thus antiarrhythmic effect of adrenomedullin was not confirmed in primary and secondary outcomes. Additionally, any differences were not detected between two groups in inflammatory cytokines and makers for myocardial injury. Severe adverse event was not occurred in this trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 3
patient receiving catheter ablation for persistent atrial fibrillation
1. paroxysmal atrial fibrillation
2. significant valvular disease
3. significant heart disease (heart failure, myocardial infarction, angina etc.)
4. hyperthyroidism
5. diameter of left atria over 50 mm
6. active infection or inflammatory disease
7. malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total time of significant atrial arrhythmias within 3 days after catheter ablation
- Secondary Outcome Measures
Name Time Method 1. rate of atrial arrhythmias within 3 days after catheter ablation<br>2. rate of atrial arrhythmias from 4 to 14 days after catheter ablation<br>3. inflammatory makers<br>4. adverse event